January 6, 2006 – Perlegen, a recent offshoot from Affymetrix, signed another deal with a major pharm/biotech, this time with Genentech to study the genetics of cancer; Genentech was a big drag on biotech averages, moving lower in advance of its earnings report next week; Repligen will bring a patent suit against Bristol-Myers Squibb over the newly approved arthritis drug Orencia; Athersys extended its collaboration with Bristol-Myers Squibb for three years; Asuragen, a new company focused on personalized medicine for cancer, was formed out of Ambion; Innovive licensed a leukemia drug, currently in pre-clinical work, from Nippon Shinyaku; and Charles River Labs licensed the xMAP technology from Luminex Corporation. The Centient Biotech 200™ was up 7 points at 4030.13, a rise of .18%. More details...
